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Reducing venous stasis ulcers by fifty percent in 10
years: The next steps
Peter Henke, MD,a,b Bob Kistner, MD,c Thomas W. Wakefield, MD,b Bo Eklof, MD,d and
Fedor Lurie, MD,c Ann Arbor, Mich; Honolulu, Hawaii; and Toledo, OhioThe focus on prevention to improve health in the
United States will increase with the recently passed health
care reform act. No one can argue that prevention of
disease is more cost effective than treatment once disease is
established. Venous disease is a perfect example of a disease
to prevent, be it venous thrombosis or the sequelae of
postthrombotic syndrome and primary venous insuffi-
ciency. Venous disease is not glamorous, but very common.
Optimistically, the knowledge and tools are available now
to significantly decrease a major morbidity of chronic ve-
nous disease, namely venous stasis ulcers.
The lack of interest and knowledge surrounding ve-
nous ulceration relegates this to a treat-and-ignore situa-
tion, clearly at odds with what is best for our patients. The
PVS6 summit put forth the straightforward goal of a 50%
reduction in venous ulceration by 10 years. Although clear,
accomplishing this will be a major challenge, primarily due
to a large and diffuse health care delivery system in the
United States. Further, dissemination of knowledge and
changing health care provider practice to improve care
requires extensive infrastructure and resources, all costing
money and time.
Nonetheless, the first step forward to accomplishing
any goal is defining a strategic plan. Herein, the four
proceeding articles in this supplement describe the current
state and gaps in knowledge, and expert consensus discus-
sion in ways to move forward (some easy, some not), and
potential barriers. Several themes are dominant: better
understanding of the disease process and natural history;
promotion of the current evidence-based guidelines for
prevention and treatment; and education of frontline phy-
sicians and the public with relation to this disease.
An optimistic time line has been put forth (Fig). The
other critical component of this proposal is engagement of
interested and like practitioners of all types and researchers.
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doi:10.1016/j.jvs.2010.05.081This proposal is inclusive, and feedback from the steering
committee is welcome as we move forward. We will also be
enlisting insurers and agencies to assist with these aims,
including industry playing a major role. The American
Venous Forum (AVF) and PVS6 Committee are commit-
ted to this goal and look forward to its progress.
1. Major program of awareness of venous ulcer (VU) and
chronic venous disease (CVD) both professional and
public:
A. Major public relations program for VU and CVD,
eg, similar to peripheral arterial disease awareness
program.
B. Major education of physicians to educate about life-
long progression of C2 and of C4 to 6. Target
physician groups from vascular surgery to primary
care to include: surgeons, general and vascular; in-
ternists and family practice; dermatologists; inter-
ventionalists; wound care physicians; and venous
specialists.
C. Produce and distribute guidelines for management of
venous ulcers including primary and secondary CVD.
2. Standardize diagnosis of CVD:
A. Ultrasound scans: practical and reproducible scans
to identify axial/segmental valvular reflux and phle-
bitis/obstruction.
B. Noninvasive and invasive diagnosis of iliac obstruc-
tive disease.
C. Work with wound care centers to diagnose and treat
VU by these standards.
3. Prevention of the postthrombotic syndrome:
A. Providing appropriate compression, ambulation,
and anticoagulation for acute DVT and prevention
of recurrent DVT.
B. Early thrombus removal in patients with iliofemoral
DVT.
C. Elimination of postthrombotic iliocaval obstruction.
D. Stratifying patients with acute DVT who are at risk
to develop severe postthrombotic syndrome.
4. Treatment of C4 to 6, including VU: compression,
correction, and surveillance guidelines:
A. Compression to control venous/lymphatic swelling.
B. Correction of superficial axial reflux, perforator re-
flux, and treatable deep vein obstruction when
symptomatic or skin changes occur.
C. Correction of deep vein reflux when correction of
superficial and perforator reflux is not sufficient.
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pliance with compression, pharmacologic management
of anticoagulation for various stages of CVD.
5. Research:
A. Develop programs and initiate action to determine the
number of VU at baseline of this 10-year initiative.
B. Natural history of primary disease progression from
C2 to C6 and the effect of early intervention to
prevent this progression. Adequately powered to
provide level 1 evidence for results of the study.
C. Markers for:
1. Cases of acuteDVT that are likely to progress toC4
to 6 stage of CVD and the postthrombotic syn-
drome.
2. Factors other than hemodynamic for progression of
disease, eg, inflammatory, genetic, molecular.
6. Organizational:
A. Create responsible organization to oversee, coordi-
Fig. Projected time line to accomplish the overarching
diagnosis; PTS, postthrombotic syndrome; VSU, venousnate, and adjust a 10-year program. Empower thisbody with authority to act and work with industry,
insurance, government, and interface with AVF.
Committee should report to AVF/AVF Foundation
and have representation from both boards, but be
separate from both boards. It should include repre-
sentatives outside of AVF including industry.
B. Initiative to influence health care policy, reimburse-
ments for medical diagnosis and treatment, and in-
surance policy.
C. Empower this body to work with industry, govern-
ment, insurance, and medical sources to fund Pacific
Vascular Symposium programs.
of VSU reduction. CVD, Chronic venous disease; dx,
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